MINNEAPOLIS, May 31, 2022 /PRNewswire/ — HistoSonics, (www.histosonics.com), the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the fulfillment of patient enrollment required for regulatory submission of their Edison™ system to the US Food and Drug Administration (FDA). The company plans to use safety and efficacy data from combined parallel […]
